Clinical trials: TACE, completed
Hepatocellular Carcinoma
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads
This pilot clinical trial compares the use of contrast-enhanced ultrasound to contrast-enhanced magnetic response imaging (MRI), the current clinical standard, in predicting treatment response in patients with liver cancer…
- Trial name
- NCT03045497
- Testing
- Perflutren Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Contrast-enhanced Magnetic Resonance Imaging
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Unresectable Hepatocellular Carcinoma
Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more than 28%. After diagnosis, the average survival rate of patient is less than 50% in 6 month, less than 24% in 1 year and 5% in 5 year.
- Trial name
- NCT00829465
- Testing
- Licartin, Transcatheter arterial chemoembolization
- Volunteers
- 400 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility and safety of using small beads (70-150 micron in place of 100-300 micron) to deliver chemotherapy into the liver to treat patients with hepatocellular carcinoma (HCC).
- Trial name
- DEBDOX (NCT02007954)
- Testing
- DEBDOX
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence
Hepatectomy is still the most important treatment for HCC.High recurrence rate mostly influence it's prognosis, especially for the patient with tumor >5cm, multiple tumor and who cannot accept R0 resection.Our retrospective study…
- Trial name
- NCT00817895
- Testing
- sustained released 5-FU and sustained released cisplatin, sustained released 5-FU, TACE
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
evaluate the prognostic value of genetic polymorphisms in HCC Egyptian patients undergoing TACE using lipiodol and doxorubicin.
- Trial name
- NCT05291338
- Testing
- Doxorubicin, Lipiodol
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Rehab Werida
Huge Hepatocellular Carcinoma (HCC) (>10cm)
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system.
- Trial name
- NCT07639294
- Testing
- hepatectomy without immune checkpoint inhibitors-based adjuvant therapy, hepatectomy with immune checkpoint inhibitors-based adjuvant therapy, neoadjuvant conversion therapy followed by surgery
- Where
- China
- Volunteers
- 715 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
ThinkRadial: A Prospective Study of Transradial deTACE in HCC Patients
This study is a prospective, observational clinical trial designed to evaluate the feasibility, safety, and effectiveness of performing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using a transradial…
- Trial name
- ThinkRADIAL (NCT07160374)
- Testing
- Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE)
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma
Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Indication : Hepatocellular carcinoma, maximum size 9 cm, with single or multiple nodes whose total tumor mass can technically be irradiated, non-resectable, and not a candidate for percutaneous therapy with recommended treatment…
- Trial name
- TACERTE (NCT01300143)
- Testing
- TACE, TACE+ RTC
- Where
- 18 sites in France
- Volunteers
- 126 people
- Sponsor
- Nantes University Hospital
Unresectable Hepatocellular Carcinoma
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- TACE (NCT02006030)
- Testing
- ADI-PEG 20, Transarterial chemoembolization
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Polaris Group
Hepatocellular Carcinoma
A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma
The propose of this study is evaluate the safety and efficacy of MG4101 (allogeneic Natural killer cells) in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).
- Trial name
- NCT02854839
- Testing
- MG4101
- Where
- 6 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma, Sorafenib
TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma
The study is a multicenter phase III randomized trial. The purpose is to investigate both the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib versus TACE alone for recurrent intermediate…
- Conditions
- Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization
- Trial name
- TREAT (NCT04103398)
- Testing
- TACE+sorafenib, TACE
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Cancer, Hepatocellular
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver…
- Trial name
- CheckMate 74W (NCT04340193)
- Testing
- nivolumab, ipilimumab, TACE
- Where
- 107 sites in United States, Australia and 17 more
- Volunteers
- 26 people
- Sponsor
- Bristol-Myers Squibb
Circulating Tumor Cell;, Hepatocellular Carcinoma
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
Circulating tumour cell (CTC) count could reflect the effect of postoperative transarterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) recurrence.
- Trial name
- NCT02032368
- Testing
- transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Guangdong Provincial People's Hospital
Hepatocellular Carcinoma
LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)
The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearls for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE…
- Trial name
- NCT03053596
- Testing
- DEB-TACE using anthracyclin loaded LifePearl™
- Where
- 7 sites in Belgium, France
- Volunteers
- 102 people
- Sponsor
- Terumo Europe N.V.
Primary Hepatocellular Carcinoma
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA)…
- Trial name
- DC-TC (NCT01828762)
- Testing
- DC-TC+GM-CSF
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai AbelZeta Ltd.
Hepatocellular Carcinoma
LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Advanced HCC represents a high unmet medical need with a poor prognosis and few therapeutic options. Patients who present with HCC beyond the currently accepted Milan criteria are not eligible to be listed for liver…
- Trial name
- HCC (NCT00877071)
- Testing
- LC Bead loaded with doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Carcinoma, Hepatocellular
Fingerprint Characterization of Advanced HCC
This single center, open-label, uncontrolled, non-randomized observational study in patients with advanced HCC. The patients qualify either to a local treatment with transarterial chemoembolization (TACE) or to a systemic…
- Trial name
- e:Med-HCC-1 (NCT02372162)
- Testing
- Image Fingerprint, Molecular Fingerprint
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- University Hospital Tuebingen
Hepatocellular Carcinoma
Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
Percutaneous, image-guided tumor ablation has evolved as a genuine alternative for the treatment of unresectable hepatocellular carcinoma.
- Trial name
- CEAL (NCT00807300)
- Testing
- CT-guided brachytherapy, transarterial chemoembolization
- Where
- Germany
- Volunteers
- 77 people
- Sponsor
- University of Magdeburg
Liver Cancer, Metastatic Cancer
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment.
- Trial name
- NCT00739167
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Northwestern University